U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336823) titled 'JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma' on Jan. 04.
Brief Summary: This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY232 injection in the treatment of relapsed/refractory multiple myeloma.
Study Start Date: Jan. 20
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: JY232 Injection
This open-label, single-arm study is designed to evaluate the efficacy and safety of an in vivo ...